Trials / Unknown
UnknownNCT04692363
Plasmapheresis Before Rituximab in Cryoglobulinemia
Prevention of Rituximab Related Flare by Plasmapheresis in Cryoglobulinemic Vascularitis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Initial worsening following initiation of rituximab therapy in patients with cryoglobulinemic vasculitis was described in 3.6% of cases. This worsening is often a serious condition, with high levels of mortality. The objective of our study is to evaluate the efficacy of preventive plasmapheresis prior to the introduction of rituximab performed in Montpellier France since 2013 by assessing the frequency and severity of this flare effect in these patients compared to those reported in the literature.
Conditions
Timeline
- Start date
- 1999-01-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-31
- First posted
- 2020-12-31
- Last updated
- 2020-12-31
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04692363. Inclusion in this directory is not an endorsement.